In a Danish multicentre trial we compared the relapse preventing effects of olsalazine and sulphasalazine in patients with ulcerative colitis over a 12 month treatment period. Two hundred and twenty seven patients (118 men) with at least two previous attacks of ulcerative colitis were randomly allocated according to a prearranged treatment schedule to olsalazine 500 mg bd or sulphasalazine 1 g bd in a double blind, double dummy fashion. One 
Sulphasalazine is widely accepted as the drug of choice for ulcerative colitis, for maintenance of remission and for treatment of mild attacks.
Over a six month period patients receiving sulphasalazine (2 g) had less than one quarter (<25%) the relapse rate of those receiving placebo. ' Unfortunately, sulphasalazine can cause a varied spectrum of adverse effects in 10-45% of those who are dependent upon it.2 The active therapeutic moiety of sulphasalazine is 5-ASA while sulphapyridine functions as a carrier ensuring that the 5-ASA is liberated within the colon. 3 As the majority of the adverse events of sulphasalazine are ascribed to the sulphapyridine moiety,4 extensive investigations into alternative ways of delivering 5-ASA to the colon have been carried out. Olsalazine (Dipentum) is a drug composed of two 5-ASA molecules linked together through an azo bond. The drug effectively releases two molecules of 5-ASA upon azo reduction in the colon.5 Olsalazine is of proven value in patients intolerant of sulphasalazine,67 and is also effective in patients with a mildly active ulcerative colitis. 8 Olsalazine has been shown superior to placebo in maintaining remission in patients with ulcerative colitis over a six month period.6 A recent study has shown that olsalazine is as effective as sulphasalazine for the maintenance treatment of ulcerative colitis over a six month period.9
The aim of the present study was to evaluate the relapse preventing effect of olsalazine compared with sulphasalazine over a one year * Active periods before entry Figure 1 : Relapsefrequency in relation to number ofactive periods ofthe disease before entry.
liver and renal function tests) was done before entry and after six and 12 months or at exit from the study. At each visit the number of consumed tablets were questioned. Patients ended the study after 12 month treatment or in case of relapse. They were withdrawn from the study if any side effect occurred which necessitated stopping therapy. Relapse was defined as inflammation of the rectal mucosa grade 3-4 on sigmoidoscopy (no distinct vessels in the mucosa, spontaneous bleeding and bleeding by contact with the sigmoidoscope).
Olsalazine was delivered in enteric coated tablets. Yellow 500 mg olsalazine sodium tablets coated with 50/50 of Eudragit® L+S to disintegrate in vitro at pH 6 5. Not less than 85% of the olsalazine sodium is released within 120 minutes in buffer solution pH 6 Table II shows that both groups were evenly matched for patient and disease characteristics. The rates of remission and relapse according to per protocol analysis in the olsalazine and the sulphasalazine treated groups are shown in Table  III, and Table IV shows the distribution between remission and failures according to the intentionto-treat analysis in the two groups. The relapse rate after 12 month in the olsalazine group is OLZ=olsalazine, SASP=sulphasalazine. 46-9% v 42-4% in the sulphasalazine group with a 95% confidence interval for the difference in proportions of -9% to 18%. In the combined groups (olsalazine+sulphasalazine the relapse rate in patients with more than two active periods were higher than in patients with two active periods (49% v 30% p=0 02). From the life-table (Fig 2) it appears, that the cumulative relapse rate is similar in both groups, and that the time span from entry into the study to relapse is similar in each group (p=0 54). There was no relation between relapse frequency and the extent of the disease or of a remission period of more or less than three months. There were no clinically significant alterations in any of the haematological or biochemical variables as measured from the blood tests in either of the two groups.
Discussion
For many years sulphasalazine has been the mainstay of relapse preventing therapy in ulcerative colitis.'0 Previously olsalazine was found superior to placebo as a maintenance agent,6 and in the present double blind controlled study we have shown that olsalazine was equally effective as sulphasalazine. In both treatment groups remission was maintained throughout a year in a little more than half of the patients. The high number of patients incorporated in our investigation yields a low risk of clinically significant type 2 error. Our study confirms and extends the findings of Ireland et al,9 who used the same dosages of sulphasalazine and olsalazine. They found, however, a lower half year relapse rate than we did. The reason is likely to be that the patients in their study had a remission of at least six months before entering the study compared with only one month in this study. Furthermore, our patients had a relatively high tendency to recurrence as we only included patients with a medical history of at least two previous attacks of ulcerative colitis.
We did not include histological assessment of rectal biopsies in our evaluation of disease activity. The reason was that there is a poor correlation between histological appearance and clinical sigmoidoscopic state. " Histological improvement lags behind improvement in symptoms and sigmoidoscopic appearance,6 and histological relapse precedes clinical deterioration. ' Several studies, mostly in patients intolerant of sulphasalazine, have shown that olsalazine is superior to placebo in the treatment of mild to moderately active ulcerative colitis. '12-14 In a few investigations olsalazine was compared with sulphasalazine.'5 16 No difference in drug efficacy could be detected. These studies comprised relatively few patients, however, and this is why minor differences in effect rate could easily be overlooked. Seven per cent of the patients were withdrawn from the trial because of adverse drug reactions. The events were minor and their incidence was the same in the two treatment groups. Patients who previously were found intolerant of sulphasalazine were excluded from the study. This resulted in a selection of patients which with regard to side effects was in favour of sulphasalazine. The tolerability of olsalazine may therefore be even more favourable. In a study of patients presenting with first attack of ulcerative colitis Rao et al found that olsalazine was better tolerated than sulphasalazine in doses releasing equal amounts of 5-ASA. 16 Diarrhoea is the most common side effect of olsalazine, occurring in some studies with a frequency of 12%61 or greater.'4 The occurrence of diarrhoea is a dose related event and it is more common in patients with extensive colitis. 6 Experiments in animals and in human ileostomy patients have shown that olsalazine acts as a secretagogue in the small intestine increasing the fluid load to the colon. '7 20 An acceleration of gastrointestinal transit may partly be responsible for the diarrhoea.2' Only 5% of our patients treated with olsalazine complained of diarrhoea (three with proctitis and two with proctisigmoiditis). That was marginally more than among those who received sulphasalazine, and the difference was not significant. The low incidence of diarrhoea may reflect the low dosage of olsalazine used and the limited extent of the colitis exhibited in the majority of patients. Furthermore, an enterit coated tablet formulation of olsalazine was used here compared with a gelatine capsule in the study by Ireland.9 We conclude that olsalazine 500 mg bd is equally effective and has the same incidence of adverse reactions as sulphasalazine 1 g bd in the maintenance therapy of ulcerative colitis. Because patients who previously were found intolerant of sulphasalazine were excluded from the study, olsalazine may in fact be more tolerable.
